CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL).

被引：0
|
作者：
Rawstron, AC
Davies, FE
Evans, P
Morgan, GJ
Jamil, A
Galvin, MC
Haynes, AP
Hale, G
Hillmen, P
机构：
[1] UNIV LEEDS,GEN INFIRM,DEPT HAEMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND
[2] PINDERFIELDS GEN HOSP,WAKEFIELD,ENGLAND
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2356 / 2356
页数：1
相关论文
共 50 条
  • [1] CAMPATH1H therapy for patients with refractory chronic lymphocytic leukaemia (CLL)
    Rawstron, AC
    Davies, FE
    Evans, PA
    Jamil, A
    Galvin, MC
    Haynes, AP
    Hale, G
    Morgan, GJ
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 : 46 - 46
  • [2] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
  • [3] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Lundin, J
    Björkholm, M
    Celsing, F
    Hale, G
    Hjalmar, V
    Kimby, E
    Tullgren, O
    Waldman, H
    Mellstedt, H
    Österborg, A
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [4] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Mellstedt, H
    Österborg, A
    Lundin, J
    Björkholm, M
    Celsing, F
    Hagberg, H
    Hast, R
    Hjalmar, V
    Kimby, E
    Luthman, M
    Tullgren, O
    Werner, B
    BLOOD, 1998, 92 (10) : 490A - 490A
  • [5] Monitoring of residual disease after CAMPATH-1H therapy of refractory chronic lymphocytic leukaemia.
    Rawstron, AC
    Davies, FE
    Morgan, GJ
    Haynes, AP
    Russell, NH
    Hale, G
    Hillmen, P
    BLOOD, 1998, 92 (10) : 105A - 105A
  • [6] Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine.
    Keating, MJ
    Byrd, J
    Rai, K
    Flinn, I
    Jain, V
    Binet, JL
    Bolin, R
    Hillmen, P
    Hutchinson, M
    BLOOD, 1999, 94 (10) : 705A - 705A
  • [7] Continuous infusion/subcutaneous alemtuzumab (Campath-1H) plus rituximab is active for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
    Faderl, S
    Ferrajoli, A
    Wierda, W
    Ravandi, F
    O'Brien, S
    Manero, GG
    Thomas, DA
    Browning, ML
    Keating, MJ
    BLOOD, 2005, 106 (11) : 831A - 831A
  • [8] Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL).
    Cao, TM
    Nguyen, DD
    Dugan, K
    Starcher, SA
    Fechter, RL
    Coutre, SE
    BLOOD, 2001, 98 (11) : 366A - 366A
  • [9] Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia
    Lin, TS
    Flinn, IW
    Lucas, MS
    Porcu, P
    Sickler, J
    Moran, ME
    Lucas, DM
    Heerema, NA
    Grever, MR
    Byrd, JC
    LEUKEMIA, 2005, 19 (07) : 1207 - 1210
  • [10] Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia
    T S Lin
    I W Flinn
    M S Lucas
    P Porcu
    J Sickler
    M E Moran
    D M Lucas
    N A Heerema
    M R Grever
    J C Byrd
    Leukemia, 2005, 19 : 1207 - 1210
12345